

## Publications:

### 2019

Kähm, K.; **Stark, R.G.**; Laxy, M.; Schneider, U.; Leidl, R. Assessment of excess medical costs for persons with type 2 diabetes according to age groups: An analysis of German health insurance claims data. *Diabetic Med.*, accepted (2019)

Olm, M.; Stark, R.G.; Beck, N.; Röger, C.; Leidl, R. Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type 2 diabetes: A systematic review. *Nutr. Rev.*, accepted (2019)

### 2018

Lennerz, B.S.; Moss, A.; von Schnurbein, J.; Bickenbach, A.; Bollow, E.; Brandt, S.; Luetke-Brintrup, D.; Mühlig, Y.; Neef, M.; Ose, C.; Remy, M.; **Stark, R.G.**; Teuner, C.M.; Wolters, B.; Kiess, W.; Scherag, A.; Reinehr, T.; Holl, R.W.; Holle, R.; Wiegand, S.; Hebebrand, J.; Wabitsch, M. Do adolescents with extreme obesity differ according to previous treatment seeking behavior? The Youth with Extreme obesity Study (YES) cohort. *Int. J. Obes.*, accepted (2018)

Bamberger, C.; Rossmeier, A.; Lechner, K.; Wu, L.; Waldmann, E.; Fischer, S.; **Stark, R.G.**; Altenhofer, J.; Henze, K.; Parhofer, K.G. A walnut-enriched diet affects gut microbiome in healthy caucasian subjects: A randomized, controlled trial. *Nutrients* 10:244 (2018)

Huber, M.B.; Präger, M.; Coyle, K.; Coyle, D.; Lester-George, A.; Trapero-Bertran, M.; Nemeth, B.; Cheung, K.L.; **Stark, R.G.**; Vogl, M.; Pokhrel, S.; Leidl, R. Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: Results from the EQUIPTMOD. *Addiction* 113, 1, 52-64 (2018)

### 2017

Bamberger, C.; Rossmeier, A.; Lechner, K.; Wu, L.; Waldmann, E.; **Stark, R.G.**; Altenhofer, J.; Henze, K.; Parhofer, K.G. A walnut-enriched diet reduces lipids in healthy caucasian subjects, independent of recommended macronutrient replacement and time point of consumption: A prospective, randomized, controlled trial. *Nutrients* 9:1097 (2017)

Laxy, M.; **Stark, R.G.**; Peters, A.; Hauner, H.; Holle, R.; Teuner, C.M. The non-linear relationship between BMI and health care costs and the resulting cost fraction attributable to obesity. *Int. J. Environ. Res. Public Health* 14:984 (2017)

Timmer, A.; **Stark, R.G.**; Peplies, J.; Classen, M.; Laass, M.W.; Koletzko, S. Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease: A survey-based analysis on 1280 patients aged 10-25 years focusing on differences by age of onset. *Eur. J. Gastroenterol. Hepatol.* 29, 1276-1283 (2017)

### 2016

Yates, N.; Teuner, C.M.; Hunger, M.; Holle, R.; **Stark, R.G.**; Laxy, M.; Hauner, H.; Peters, A.; Wolfenstetter, S.B. The economic burden of obesity in Germany: Results from the population-based KORA studies. *Obes. Facts* 9, 397-409 (2016)

Ulrich, S.; Holle, R.; Wacker, M.; **Stark, R.**; Icks, A.; Thorand, B.; Peters, A.; Laxy, M. The cost burden of type 2 diabetes in Germany – Results from the population-based KORA Studies. *BMJ Open* 6:e012527 (2016)

## 2015

Xu T, Brandmaier S, Herder C, Messias A, Draisma H, Demirkan A, Yu Z, Ried J, Haller T, Heier M, Campillos M, Fobo G, **Stark R**, Holzapfel C, Adam J, Chi S, Rotter M, Panni T, Quante A, He Y, Prehn C, Roemisch-Margl W, Kastenmüller G, Willemsen G, Pool R, Kasa K, van Dijk Ko W, Hankemeier T, Meisinger C, Thorand B, Ruepp A, Hrabé de Angelis M, Li Y, Wichmann E, Stratmann B, Strauch K, Metspalu A, Gieger C, Suhre K, Adamski J, Illig T, Rathmann W, Roden M, Peters A, van Duijn C, Boomsma D, Meitinger T, Wang-Sattler R. Effects of metformin on metabolite profiles and LDL cholesterol in type 2 diabetes patients. *Diabetes Care*. 2015, 38(10): 1858-1867.

Laxy M, **Stark R**, Meisinger C, Kirchberger I, Heier M, von Scheidt W, Holle R. The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: Results from an observational longitudinal study. *Diabetol Metab Syndr*. 2015, 7: 77.

Laxy, M., Hunger, M., Thorand, B., Meisinger, C., Kirchberger, I., **Stark, R.**, Holle, R.: The Burden of Diabetes Mellitus in Patients with Coronary Heart Disease: A Methodological Approach to Assess Quality-Adjusted Life-Years Based on Individual-Level Longitudinal Survey Data. *Value in Health*. 2015 18(8): 969-976

Schunk, M., **Stark, R.**, Reitmeir, P., Meisinger, C., Holle, R.: Towards patient-oriented diabetes care: Results from two KORA surveys in Southern Germany. *Journal of Diabetes Research* 2015 <http://dx.doi.org/10.1155/2015/368570>

## 2014

**Stark, R.**, Kirchberger, I., Heier, M., Leidl, R., von Scheidt, W., Meisinger, C., Holle, R.: Improving care of post-infarct patients: effects of disease management programs and care according to international guidelines. *Clinical Research in Cardiology*. 2014; 103(3): 237-45

Wu L, Piotrowski K, Rau T, Waldmann E, Broedl UC, Demmelmair H, Koletzko B, **Stark RG**, Nagel JM, Mantzoros CS, Parhofer KG. Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: A randomized controlled cross-over clinical trial. *Metabolism*. 2014 Mar;63(3):382-91. (Epub: 2013, Nov 12)

## 2013

Claessen, H., Strassburger, K., Tepel, M., Waldeyer, R., Chernyak, N., Jülich, F., Albers, B., Baechle, C., Rathmann, W., Meisinger, C., Thorand, B., Hunger, M., Schunk, M., **Stark, R.**, Rückert, I.M., Peters, A., Huth, C., Stöckl, D., Giani, G., Holle, R., Icks, A.: Medication costs by glucose tolerance stage in younger and older women and men: Results from the population-based KORA survey in Germany. *Exp Clin Endocrinol Diabetes*. 2013 Nov;121(10):614-23

Icks, A., Claessen, H., Strassburger, K., Tepel, M., Waldeyer, R., Chernyak, N., Albers, B., Baechle, C., Rathmann, W., Meisinger, C., Thorand, B., Hunger, M., Schunk, M., **Stark, R.**, Rückert, I.M., Peters, A., Huth, C., Stöckl, D., Giani, G., Holle, R.: Drug costs in prediabetes and

undetected diabetes: results from the population-based KORA survey in Germany. (Letter)  
Diabetes Care 36:e53-54 (2013)

**Stark, R.**, Holle, R. Mittelfristige Effekte von DMP-KHK, Abschlussbericht an AOK

## 2012

Leidl, R., Reitmeir, P., König, H.-H., **Stark, R.** The Performance of a Value Set for the EQ-5D Based on Experienced Health States in Patients with Inflammatory Bowel Disease. *Value In Health*. 2012; 15: 151–157

Nagel, J. M., Bücker, S., Wood, M., **Stark, R.**, Göke, B., Parhofer, K. G., Allgayer, H. Less Advanced Stages of Colon Cancer in Patients with Type 2 Diabetes Mellitus: an Unexpected Finding? *Exp Clin Endocrinol Diabetes*. Online: January 9, 2012 (DOI <http://dx.doi.org/10.1055/s-0031-1299704>)

## 2011

Bähr, I-N, Tretter, P., Krüger, J., **Stark, R. G.**, Schimkus, J., Unger, T., Kappert, K., Scholze, J., Parhofer, K. G. and Kintscher, U. High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-gamma Activated Receptor- Target Genes in Patients With the Metabolic Syndrome. *Hypertension*. 2011; 58: 725-732.

Schunk, M., **Stark, R.**, Reitmeir, P., Rathmann, W., Meisinger, C., Holle, R. Verbesserungen in der Versorgung von Patienten mit Typ-2-Diabetes? Gepoolte Analyse dreier bevölkerungsbasierter Studien (KORA) in der Region Augsburg zwischen 1999 und 2008. *Bundesgesundheitsbl*. 2011; 54: 1187–1196

**Stark, R.**, John, J, Leidl, R.: Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: A scenario approach. *BMC Health Services Research*. 2011; 11: 9

**Stark, R.**, Schunk, M., Meisinger, C., Rathmann, W., Leidl, R., Holle, R.: Medical care of type 2 diabetes in German disease management programs: a population-based evaluation. *Diabetes Metab Res Rev*. 2011; 27(4): 383-391

**Stark, R.**, Schunk, M., Holle, R.: Ergebnisse der KORA-Studien. In: Günster, C., Klose, J., Schmacke, N. (editor) *Versorgungsreport 2011 Schwerpunkt: Chronische Erkrankungen*. Schattauer Verlag, Stuttgart, 78-83 (2011)

## 2010

Findeisen, H.M., Weckbach, S., **Stark, R.G.**, Reiser, M.F., Schoenberg, S.O., Parhofer, K.G.: Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. *Cardiovascular Diabetology*. 2010; 9: 44

**Stark, R.**, Reitmeir, P., Leidl, R., König HH.: Validity, Reliability, and Responsiveness of the EQ-5D in Inflammatory Bowel Disease in Germany. *Inflammatory Bowel Disease*. 2010; 16: 42-51

Parhofer, K.G., Zeymer, U., **Stark, R.G.**, Binz, C., Schwertfeger, M., Bhatt, D. L., Steg, Ph. G., Röther, J.: In Germany Diabetic Patients with Coronary Artery Disease are Treated More Intensively than Diabetic Patients with Other Manifestations of Atherothrombosis – Results from the REACH Registry. *Exp Clin Endocrinol Diabetes*. 2010; 118: 51 – 56

## 2009

**Stark, R.**, Schunk, M., Leidl, R., Meisinger, C., Holle, R.: Prozessevaluation von Disease Management Programmen bei Typ 2 Diabetes auf Basis einer bevölkerungsrepräsentativen Studie in der Region Augsburg (KORA). *Betriebswirtschaftliche Forschung und Praxis*. 2009; 61 (3): 283-301

Weckbach, S., Findeisen, H.M., Schoenberg, S.O., Kramer, H., **Stark, R.**, Clevert, D.A., Reiser, M.F., Parhofer, K.G.: Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus: Comprehensive Assessment With Whole-Body Magnetic Resonance Imaging/Magnetic Resonance Angiography. *Invest Radiol*. 2009; 44: 242–250

Broedl, U.C., Leberherz, C., Lehrke, M., **Stark, R.**, Greif, M., Becker, A., von Ziegler, F., Tittus, J., Reiser, M., Becker, C., Göke, B., Parhofer, K., Leber, A.W.: Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques. *PLoS ONE*. 2009; 4(3)

## 2008

Lehrke M, Konrad A, Schachinger V, Tillack C, Seibold F, **Stark R**, Parhofer IG, Broedl UC. CXCL16 is a surrogate marker of inflammatory bowel disease. *Scand J Gastroenterol*. 2008; 43: 283-8.

## 2007

Konrad A, Lehrke M, Schachinger V, Seibold F, **Stark R**, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC. Resistin is an inflammatory marker of inflammatory bowel disease in humans. *Eur J Gastroenterol Hepatol*. 2007; 19: 1070-4.

Broedl UC, Schachinger V, Lingenhel A, Lehrke M, **Stark R**, Seibold F, Goke B, Kronenberg F, Parhofer KG, Konrad-Zerna A. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2007;13:391-7.

## 2006

**Stark R**, König HH, Leidl R: Costs of inflammatory bowel disease in Germany based on a cost diary. *Pharmacoeconomics*. 2006; vol. 24, no. 8: 797-814

## 2003

Von Kries R, Ihme N, Oberle D, Lorani A, **Stark R**, Altenhofen L, Niethard FU. Universal ultrasound screening programme for developmental dysplasia of the hip in Germany: impact on the rate of first operative procedures. *Lancet*. 2003; 362: 1883-1887.

Mühlberger N, Behrend C, **Stark R**, Holle R. Datenbankgestützte Online-Erfassung von Arzneimitteln im Rahmen gesundheitswissenschaftlicher Studien – Erfahrungen mit der IDOM-Software. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 2003; 4: 601-611.

**1987**

Ryan EA, **Stark R**, Crockford PM, Suthijumroon A. Assessment of Value of Glycosylated Albumin and Protein in Detection of Gestational Diabetes. Diabetes Care 1987; 10:213-216.